Humana Inc
NYSE:HUM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Humana Inc
NYSE:HUM
|
US |
|
Invex Therapeutics Ltd
ASX:IXC
|
AU |
|
Euronet Worldwide Inc
NASDAQ:EEFT
|
US |
|
I
|
Industrial and Commercial Bank of China Ltd
SWB:ICK
|
CN |
|
E
|
Evonik Industries AG
SWB:EVK
|
DE |
Earnings Calls
Last Earnings Call
On track: Management said Humana is tracking to expectations for 2026 and remains on course for its 2028 goals, including a sustainable pretax margin of at least 3%.
2027 bids: The company plans meaningful margin expansion in 2027, using benefit changes, plan exits, and ongoing cost improvements to get there.
Stars progress: Humana said its Stars operating improvements are ahead of historical trends, but it still would not predict the final October outcome because CMS thresholds are unknown.
Cost trends: 2026 medical and pharmacy cost trends are still expected to be in the 7% to 8% range, with some favorability in inpatient care.
Efficiency gains: Operating model changes, including centralization and outsourcing, are already producing hundreds of millions of dollars in value this year.
Capital moves: Humana announced a roughly $900 million Gentiva divestiture, $1.5 billion in contingent capital facilities, and a new Illinois Medicaid contract set to begin in January 2027.